The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

(2019) Sander Brooks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects

(2018) Peter D van der Ark et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

(2017) Kathryn M Connor et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Neurophysiological correlates of suicidal ideation in major depressive disorder: Hyperarousal during sleep

(2017) Michael R. Dolsen et al.   JOURNAL OF AFFECTIVE DISORDERS

Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2014) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism

(2014) Christine Dugovic et al.   Frontiers in Neuroscience

The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010

(2013) Alize J. Ferrari et al.   PLoS One

Neurogenesis-Independent Antidepressant-Like Effects on Behavior and Stress Axis Response of a Dual Orexin Receptor Antagonist in a Rodent Model of Depression

(2012) Mathieu Nollet et al.   NEUROPSYCHOPHARMACOLOGY

Minireview: Stress-Related Psychiatric Disorders with Low Cortisol Levels: A Metabolic Hypothesis

(2011) Rachel Yehuda et al.   ENDOCRINOLOGY

Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression

(2011) Mathieu Nollet et al.   NEUROPHARMACOLOGY

Insomnia and Sleep Duration in a Large Cohort of Patients With Major Depressive Disorder and Anxiety Disorders

(2010) Josine G. van Mill et al.   JOURNAL OF CLINICAL PSYCHIATRY

Hypocretin/orexin in arousal and stress

(2009) Craig W. Berridge et al.   BRAIN RESEARCH

Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat

(2009) C. Dugovic et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders

(2009) Julien Mendlewicz   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Central CRH system in depression and anxiety — Evidence from clinical studies with CRH1 receptor antagonists

(2008) Florian Holsboer et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population

(2008) Markus Jansson-Fröjmark et al.   JOURNAL OF PSYCHOSOMATIC RESEARCH

Neuronal activity of orexin and non-orexin waking-active neurons during wake–sleep states in the mouse

(2008) K. Takahashi et al.   NEUROSCIENCE

The stress system in depression and neurodegeneration: Focus on the human hypothalamus

(2007) A.-M. Bao et al.   BRAIN RESEARCH REVIEWS